AusperBio Secures $37M for HBV Therapy Development

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together known as AusperBio), a clinical-stage biotechnology company focused on developing targeted oligonucleotide therapies for chronic hepatitis B (CHB) infection, has announced the successful completion of a $37 million Series A financing round. This investment round was led by InnoPinnacle Fund and included new investors such as Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.

The newly secured funds will be utilized to advance the clinical development of AusperBio's lead product candidate, AHB-137. Additionally, the financing will support the progression of the company's proprietary Med-Oligo™ technology platform and its expanding product pipeline.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed gratitude for the support from both existing and new investors. He noted that the Series A financing round is a significant milestone, reflecting the company's scientific and clinical accomplishments. Dr. Cheng emphasized the shared commitment of the investors towards developing new therapies for CHB patients. He stated, "With this funding, together with the recent Breakthrough Therapy Designation (BTD) from China's CDE, we are well-positioned to rapidly advance the clinical development of AHB-137 and move closer to providing a vital new treatment option for patients with CHB."

About AHB-137

AHB-137 is a novel unconjugated antisense oligonucleotide (ASO) developed under AusperBio's proprietary Med-Oligo™ ASO technology platform. Designed to achieve a functional cure for chronic hepatitis B, AHB-137 has demonstrated promising preclinical and Phase 1 clinical data, which were highlighted at the 2023 EASL™ conference and the 2024 EASL™ conference, respectively. This dual-mechanism ASO is currently undergoing a Phase 1b trial at multiple international study sites, as well as a concurrent Phase 2 trial in China. Through a global development strategy, AHB-137 is making significant strides towards the goal of curing HBV.

About AusperBio

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China. The company is dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection. AusperBio has developed a proprietary Med-Oligo™ ASO platform, which has shown substantial improvements over current ASO therapeutics through innovative ASO design. By combining this platform with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform enhances ASO therapeutics to address a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

The successful completion of this Series A financing round marks a pivotal point for AusperBio as it accelerates its mission to provide new, effective treatment options for patients with chronic hepatitis B. The company's focus on leveraging its proprietary technologies and advancing clinical trials underscores its commitment to transforming the landscape of HBV treatment. As AHB-137 progresses through clinical stages, the support and confidence of the investors will be crucial in realizing the potential of this innovative therapy.

AusperBio's efforts represent a significant step forward in the quest to develop a functional cure for chronic hepatitis B, a disease that affects millions worldwide. With continued dedication and strategic investments, the company aims to bring new hope to those suffering from this persistent viral infection.